Moussa Laanani1, Jade Ghosn2, Asma Essat3, Adeline Melard4, Rémonie Seng1, Marine Gousset4, Henri Panjo3, Emmanuel Mortier5, Pierre-Marie Girard6, Cécile Goujard7, Laurence Meyer1, Christine Rouzioux8. 1. INSERM, Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University Assistance publique-Hôpitaux de Paris (AP-HP), Department of Epidemiology and Public Health, Bicêtre Hospital, Le Kremlin-Bicêtre. 2. AP-HP, Unité Fonctionnelle de Thérapeutique en Immuno-Infectiologie, Hôtel Dieu University Hospital Paris Descartes University, EA 7327, Sorbonne-Paris-Cité 3. INSERM, Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University. 4. AP-HP, Virology Department, Necker Hospital, Paris. 5. AP-HP, Department of Internal Medicine, Louis-Mourier Hospital, Colombes. 6. AP-HP, Hôpital Saint-Antoine, Service des Maladies Infectieuses et tropicales Sorbonne Universités, Université Pierre et Marie Curie INSERM, UMR_S1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris. 7. INSERM, Centre for Research in Epidemiology and Population Health, U1018, Paris-Sud University AP-HP, Department of Internal Medicine, Bicêtre Hospital, Le Kremlin-Bicêtre, France. 8. Paris Descartes University, EA 7327, Sorbonne-Paris-Cité AP-HP, Virology Department, Necker Hospital, Paris.
Abstract
BACKGROUND: Combined antiretroviral therapy (cART) initiation during primary human immunodeficiency virus (HIV) infection (PHI) yields a larger decrease in cell-associated HIV-DNA (CA-HIV-DNA) than initiation during the chronic phase. Our objective was to model the short and long-term decay of CA-HIV-DNA blood reservoir in patients initiating cART during PHI and to assess the impact of the timing of cART initiation on CA-HIV-DNA decay. METHODS: We included patients enrolled during PHI in the Agence Nationale de Recherche sur le Sida PRIMO cohort, treated within the month following enrollment and achieving sustained virologic response. The decay of CA-HIV-DNA over time while on successful cART was modeled with a 3-slope linear mixed-effects model according to the delay between estimated date of infection and cART initiation. RESULTS: Three hundred twenty-seven patients were included, accounting for 1305 CA-HIV-DNA quantifications. Median time between infection and cART initiation was 41 days (interquartile range, 33-54 days). Median follow-up under cART was 2.3 years (range, 0.4-16.6 years). The timing of cART initiation had significant impact on the first slope of decrease: The earlier cART was initiated after HIV infection, the faster CA-HIV-DNA level decreased during the first 8 months of cART: -0.171, -0.131, and -0.068 log10 copies/10(6) peripheral blood mononuclear cells (PBMCs) per month when cART was initiated 15 days, 1 month, and 3 months after infection, respectively (P < .0001). The predicted mean CA-HIV-DNA level achieved after 5 years of successful cART was 1.62 and 2.24 log10 copies/10(6) PBMCs when cART was initiated 15 days and 3 months after infection, respectively (P = .0006). CONCLUSIONS: This study provides strong arguments in favor of cART initiation at the earliest possible time point after HIV infection.
BACKGROUND: Combined antiretroviral therapy (cART) initiation during primary human immunodeficiency virus (HIV) infection (PHI) yields a larger decrease in cell-associated HIV-DNA (CA-HIV-DNA) than initiation during the chronic phase. Our objective was to model the short and long-term decay of CA-HIV-DNA blood reservoir in patients initiating cART during PHI and to assess the impact of the timing of cART initiation on CA-HIV-DNA decay. METHODS: We included patients enrolled during PHI in the Agence Nationale de Recherche sur le Sida PRIMO cohort, treated within the month following enrollment and achieving sustained virologic response. The decay of CA-HIV-DNA over time while on successful cART was modeled with a 3-slope linear mixed-effects model according to the delay between estimated date of infection and cART initiation. RESULTS: Three hundred twenty-seven patients were included, accounting for 1305 CA-HIV-DNA quantifications. Median time between infection and cART initiation was 41 days (interquartile range, 33-54 days). Median follow-up under cART was 2.3 years (range, 0.4-16.6 years). The timing of cART initiation had significant impact on the first slope of decrease: The earlier cART was initiated after HIV infection, the faster CA-HIV-DNA level decreased during the first 8 months of cART: -0.171, -0.131, and -0.068 log10 copies/10(6) peripheral blood mononuclear cells (PBMCs) per month when cART was initiated 15 days, 1 month, and 3 months after infection, respectively (P < .0001). The predicted mean CA-HIV-DNA level achieved after 5 years of successful cART was 1.62 and 2.24 log10 copies/10(6) PBMCs when cART was initiated 15 days and 3 months after infection, respectively (P = .0006). CONCLUSIONS: This study provides strong arguments in favor of cART initiation at the earliest possible time point after HIV infection.
Authors: Marilia Rita Pinzone; Erin Graf; Lindsay Lynch; Brigit McLaughlin; Frederick M Hecht; Mark Connors; Stephen A Migueles; Wei-Ting Hwang; Giuseppe Nunnari; Una O'Doherty Journal: J Virol Date: 2016-11-14 Impact factor: 5.103
Authors: Graham C Treasure; Evgenia Aga; Ronald J Bosch; John W Mellors; Daniel R Kuritzkes; Michael Para; Rajesh T Gandhi; Jonathan Z Li Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Peter D Burbelo; Richard W Price; Lars Hagberg; Hiroyu Hatano; Serena Spudich; Steven G Deeks; Magnus Gisslén Journal: J Infect Dis Date: 2018-03-13 Impact factor: 5.226
Authors: Huldrych F Günthard; Michael S Saag; Constance A Benson; Carlos del Rio; Joseph J Eron; Joel E Gallant; Jennifer F Hoy; Michael J Mugavero; Paul E Sax; Melanie A Thompson; Rajesh T Gandhi; Raphael J Landovitz; Davey M Smith; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2016-07-12 Impact factor: 56.272